The ERA-EDTA Registry Annual Report 2017: a summary
Anneke Kramer, Rianne Boenink, Marlies Noordzij, Jizzo R. Bosdriesz, Vianda S Stel, Palma Beltrán, Juan Carlos Ruiz, Nurhan Seyahi, Jordi Comas Farnés, Maria Stendahl, Liliana Gârneaţă, Rebecca Winzeler, Eliezer Golan, František Lopot, Grzegorz Korejwo, Marjolein Bonthuis, Mathilde Lassalle, María Fernanda Slon Roblero, Viktorija Kuzema, Kristine Hommel, Olivera Stojceva-Taneva, Anders Åsberg, Reinhard Kramar, Marc H. Hemmelder, Johan De Meester, Evgueniy Vazelov, Anton Andrusev, Pablo Castro de la Nuez, Jaakko Helve, Kirill Komissarov, Anna Casula, Ángela Magaz, Carmen Santiuste de Pablos, Ivan Bubić, Jamie P. Traynor, Kyriakos Ioannou, Alma Idrizi, Runólfur Pálsson, Jean-Marin Des Grottes, Viera Spustová, Miloreta Tolaj-Avdiu, F. Jarraya, Maurizio Nordio, Edita Žiginskienė, Ziad A. Massy, Kitty J. Jager
Abstract
BACKGROUND: This article presents a summary of the 2017 Annual Report of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry and describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 37 countries. METHODS: The ERA-EDTA Registry received individual patient data on patients undergoing RRT for ESRD in 2017 from 32 national or regional renal registries and aggregated data from 21 registries. The incidence and prevalence of RRT, kidney transplantation activity and survival probabilities of these patients were calculated. RESULTS: In 2017, the ERA-EDTA Registry covered a general population of 694 million people. The incidence of RRT for ESRD was 127 per million population (pmp), ranging from 37 pmp in Ukraine to 252 pmp in Greece. A total of 62% of patients were men, 52% were ≥65 years of age and 23% had diabetes mellitus as the primary renal disease. The treatment modality at the onset of RRT was haemodialysis for 85% of patients. On 31 December 2017, the prevalence of RRT was 854 pmp, ranging from 210 pmp in Ukraine to 1965 pmp in Portugal. The transplant rate in 2017 was 33 pmp, ranging from 3 pmp in Ukraine to 103 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2008-12, the unadjusted 5-year patient survival probability for all RRT modalities combined was 50.8%.